Two underlying mechanisms have been proposed to explain the observed islet graft survival associated with CD103-MC-MMAF treatment: (1) specific lymphopenia in the CD8+ T compartment and (2) a shift toward a Treg phenotype. The gene discussed is CD8A; the disease is lymphopenia.